Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Shoulder Innovations Earnings Call: Key Takeaways

Shoulder Innovations delivered a strong Q3 2026 with 38% revenue growth, raising full-year guidance on robust surgeon adoption and a broadening product pipeline despite typical seasonal headwinds.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthQ3 net revenue $16.2M, up 38% year-over-year; FY26 guidance raised to 44-48%.
Mgmt ConfidenceHigh conviction in guidance; momentum durable as they close out the year.
Demand VisibilityEncouraging start to Q4; deep funnel of 1,800 high-volume US specialists.
Margin TrendsQ3 gross margin 78.5%, up from 76.2% prior year; pricing discipline maintained.
Op. LeverageSG&A as percentage of revenue expected to increase in Q4 due investments.
Pricing PowerSustained pricing discipline; new products supporting ASP despite ASC pricing pressure.
Vol vs PriceGrowth driven by 34% implant volume increase and year-over-year ASP gains.
Segment GrowthCore surgeon category derived majority of implant volume growth this quarter.
New ClientsAdded new customers ahead of plan; 150 surgeon engagement events YTD.
Capex & DebtCash balance $92.3M; cash flow break-even expected with cash on hand.
RegulatoryFavorable CMS final rulings; INSET NEO robotics FDA submission planned H1 2027.
CommentaryFocus on 'prospect to contender to core' surgeon progression for predictable growth.
New LaunchesLaunched INSETGO, N22 Humeral Head; INSET 1 and Clutch Guide coming 2027.

Growth

Q3 revenue grew 38% to $16.2M; implant volume increased 34% to 2,126 units.

Outlook

Raised FY2026 revenue guidance to $68M-$70M, representing 44% to 48% year-over-year growth.

Risks

Management noted pronounced seasonality among tenured surgeons and pricing pressure in ambulatory surgery centers.

Source

The company's earnings call, NYSE: SI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Shoulder Innovations, Inc.: key numbers

Share price
$20.45Close, Nov 16
Market cap
$428M
Shares outstanding
20.92MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Shoulder Innovations, Inc.

All →
5:08 PM ET 10-Q
Financial Results ▶ Call

Shoulder Innovations Q3 2026 Results: Net Loss of $7.05M, Loss Narrows

Shoulder Innovations, Inc. reported net revenue of $50.07 million for the nine months ended September 30, 2026, a significant increase from $32.90 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $25.58 million for the period as it continues to invest heavily in research and development and selling, general, and administrative expenses.

Key figure
Net loss $7.05M
4:18 PM ET 8-K
Financial Results

Shoulder Innovations Financial Results

Shoulder Innovations reported Q3 2026 revenue of $16.2 million, a 38% year-over-year increase driven by higher implant system sales and surgeon adoption. The company raised its full-year 2026 revenue guidance to a range of $68 million to $70 million and highlighted the commercial launch of its N-22 humeral head.

“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving.”

Rob Ball, CEO of Shoulder Innovations

“This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”

Rob Ball, CEO of Shoulder Innovations
7:06 AM ET 8-K
Product Launch

Shoulder Innovations Product Launch

Shoulder Innovations announced the limited user release and commercial launch of InSet Go, its next-generation glenoid implant for anatomic shoulder arthroplasty. The launch follows the successful completion of the first surgical case and aims to improve procedural efficiency while maintaining the company's clinically-proven design for implant stability.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.